Pharmafile Logo
Pharmafocus logo
Advanced Search

Regeneron

Showing 15 posts of 105 posts found.

Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria

September 26, 2025
Research and Development Dupixent, Regeneron, Sanofi, urticaria

Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human …

News
clinical_trials

Dupixent improves symptoms in patients with skin of colour, study shows

June 11, 2025
Advocacy Development, Medical Education, Research and Development Dermatology, Dupixent, Regeneron, Sanofi, atopic dermatitis, dermatology, underserved populations

Sanofi and Regeneron have announced results from the collaborative phase 4 DISCOVER study, presented at the Revolutionizing Atopic Dermatitis Conference, …

News

Dupixent approved as first biologic medicine in Japan for COPD patients

April 2, 2025
Research and Development COPD, Chronic Diseases, Regeneron, Sanofi, biotech, respiratory disease

The Ministry of Health, Labour and Welfare in Japan has authorised marketing and manufacturing of Dupixent (dupilumab) for the treatment …

News

Regeneron and Mammoth Biosciences announce CRISPR collaboration

April 26, 2024
Research and Development Pharmacy, Regeneron, crispr, gene editing

Regeneron Pharmaceuticals and Mammoth Biosciences have announced a collaboration for the research, development and commercialisation of in vivo CRISPR-based gene …

News

FDA accepts BLA for Regeneron’s linvoseltamab for Priority Review

February 22, 2024
Medical Communications FDA, Oncology, Regeneron, bla, priority review

Regeneron Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for …

News

Regeneron’s linvoseltamab gains EMA filing acceptance for R/R MM treatment

February 5, 2024
Medical Communications EMA, Oncology, Regeneron, linvoseltamab, multiple myeloma

Regeneron Pharmaceuticals has announced that the European Medicines Agency (EMA) has accepted for review its Marketing Authorisation Application (MAA) for …

News
louis-reed-pwckf7l4-no-unsplash_5

Regeneron forms Regeneron Cell Medicines with acquisition of 2seventy bio

January 31, 2024
Business Services 2seventy bio, Pharmacy, Regeneron, Regeneron Cell Medicines, acquisition

Regeneron Pharmaceuticals has announced the formation of Regeneron Cell Medicines based on an agreement with 2seventy bio to acquire the …

News

Regeneron shares data for multiple myeloma treatment

December 8, 2023
Medical Communications Cancer, Oncology, Regeneron, clinical trial

Regeneron Pharmaceuticals has announced positive data from the pivotal LINKER-MM1 trial which assessed linvoseltamab as a treatment for patients with …

News

Regeneron plans to share advancements from blood cancer pipeline

November 6, 2023
Medical Communications ASH annual meeting, Haematology, Regeneron, blood cancer, haematology

Regeneron Pharmaceuticals have announced that it plans to share new and updated data from its haematology pipeline at the American …

News

Regeneron and Sanofi’s sBLA for Dupixent accepted by FDA for priority review

September 26, 2023
Medical Communications Dupixent, Ear Nose & throat, FDA, Regeneron, Sanofi

Regeneron Pharmaceuticals and Sanofi have announced that the US Food and Drug Administration (FDA) has accepted their supplemental Biologics License …

News
eye_2

Regeneron shares two-year PULSAR trial results for wAMD

August 11, 2023
Medical Communications Opthalmology, PULSAR trial, Regeneron, wAMD

Regeneron Pharmaceuticals have announced positive, two-year, topline results from its PULSAR trial assessing aflibercept 8mg for the treatment of patients …

News

Regeneron’s drug cocktail shown to prevent symptomatic COVID-19

April 13, 2021
Manufacturing and Production COVID-19, REGEN-COV, Regeneron, covid-19 treatment, pharma, pharma news

Regeneron’s REGEN-COV treatment cocktail for COVID-19, a combination between casirivimab and imdevimab, has shown a significant reduction in progression to …

News
libtayo

Phase III trial of Libtayo stopped early after positive overall survival results

March 15, 2021
Sales and Marketing Cancer, Libtayo, Regeneron, Sanofi

A Phase III trial of Sanofi and Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) will be stopped early after positive results demonstrated …

News
ipos0_l

FDA approves Regeneron’s Evkeeza for HoFH

February 12, 2021
Medical Communications FDA, Regeneron

The FDA has approved Regeneron’s Evkeeza (evinacumab-dgnb) as an adjunct to other low-density lipoprotein cholesterol (LDL-C) lowering therapies to treat …

News
ipos0_l

Regeneron announces initial clinical data for COVID-19 antibody cocktail

December 18, 2020
Medical Communications COVID-19, Regeneron, antibody

Regeneron Pharmaceuticals has announced that initial clinical data published in the New England Journal of Medicine shows that its antibody …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025